Concurrent chemoradiotherapy with carboplatin and uracil–ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx

This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy as a primary treatment modality for larynx preservation in patients with stage two squamous cell carcinoma (SCC) of the glottic larynx. Between February 2000 and August 2003, a total of 20 patients received concurrent chemoradiotherapy. Carboplatin was given intravenously once a week during the period of radiotherapy. The weekly carboplatin dose was based on the area under the curve 1 to 1.25. Uracil–ftegafur (UFT) was given in a daily oral dose of 300 mg as tegafur. Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gray (Gy), to a total dose of 66–72 Gy. The three-year overall survival rate with larynx preservation was 100 per cent. Concurrent chemoradiotherapy with carboplatin and UFT for stage two SCC of the glottic larynx was safe and effective in improving local control with larynx preservation.

[1]  A. Garden,et al.  Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment? , 2003, International journal of radiation oncology, biology, physics.

[2]  T. Taguchi,et al.  Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma. , 2003, Anticancer research.

[3]  W. Mendenhall,et al.  T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Guelfucci,et al.  Partial Frontolateral Laryngectomy With Epiglottic Reconstruction for Management of Early‐Stage Glottic Carcinoma , 2001, The Laryngoscope.

[5]  C. Meeuwis,et al.  CO2‐laser treatment of recurrent glottic carcinoma , 2001, Head & neck.

[6]  P. Nicolai,et al.  Endoscopic CO2 Laser Excision for Tis, T1, and T2 Glottic Carcinomas: Cure Rate and Prognostic Factors , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[7]  I. Zink,et al.  Voice quality after narrow-margin laser cordectomy compared with laryngeal irradiation , 1999, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[8]  R. Garrel,et al.  Modified subtotal laryngectomy with cricohyoidoepiglottopexy—long term results in 81 patients , 1999, Head & neck.

[9]  R. Bristow,et al.  T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. , 1998, International journal of radiation oncology, biology, physics.

[10]  J. Quivey,et al.  Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. , 1997, International journal of radiation oncology, biology, physics.

[11]  M. Nakamizo,et al.  Partial laryngectomy in the treatment of radiation‐failure of early glottic carcinoma , 1997, Head & neck.

[12]  G Motta,et al.  T1-T2-T3 glottic tumors: fifteen years experience with CO2 laser. , 1997, Acta oto-laryngologica. Supplementum.

[13]  Y. Nishimura,et al.  Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  R. Rydell,et al.  Voice evaluation before and after laser excision vs. radiotherapy of T1A glottic carcinoma. , 1995, Acta oto-laryngologica.

[15]  A. Becker.  [Comparative voice results after laser resection or irradiation of T1 vocal cord carcinoma]. , 1995, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[16]  W. Curran,et al.  Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W. Mendenhall,et al.  T1-T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control. , 1993, International journal of radiation oncology, biology, physics.

[18]  T. Teshima,et al.  Prognostic factor of telecobalt therapy for early glottic carcinoma , 1992, Cancer.

[19]  B. Kimler,et al.  5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. , 1991, International journal of radiation oncology, biology, physics.

[20]  L. Peters,et al.  T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy. , 1990, Archives of otolaryngology--head & neck surgery.

[21]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Hirano,et al.  Vocal Function following Hemilaryngectomy , 1987, The Annals of otology, rhinology, and laryngology.

[23]  E. Alba,et al.  Carboplatin, an active drug in advanced head and neck cancer. , 1986, Cancer treatment reports.

[24]  R. Donehower,et al.  Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Douple,et al.  Carboplatin as a potentiator of radiation therapy. , 1985, Cancer treatment reviews.

[26]  Z. Siddik,et al.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. , 1984, Cancer research.

[27]  J. Byfield,et al.  Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. , 1982, International journal of radiation oncology, biology, physics.